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To date, little evidence of miRNAexpression/
deregulation in multiple myeloma has been
reported. To characterize miRNA in the con-
text of the major multiple myeloma molecu-
lar types, we generated miRNA expression
profiles of highly purified malignant plasma
cells from 40 primary tumors. Furthermore,
transcriptional profiles, available for all pa-
tients, were used to investigate the occur-
rence of miRNA/predicted target mRNA
pair anticorrelations, and the miRNA and
genome-wide DNA data were integrated in a
subset of patients to evaluate the influence
of allelic imbalances on miRNA expression.
Differential miRNAexpression patterns were
identified, which were mainly associated
with the major IGH translocations; particu-
larly, t(4;14) patients showed specific over-
expression of let-7e, miR-125a-5p, and
miR-99b belonging to a cluster at 19q13.33.
The occurrence of other lesions (ie, 1q gain,
13q and 17p deletions, and hyperdiploidy)
wasslightlycharacterizedbyspecificmiRNA
signatures. Furthermore, the occurrence of
several allelic imbalances or loss of het-
erozygosity was found significantly associ-
ated with the altered expression of miRNAs
located in the involved regions, such as
let-7b at 22q13.31 or miR-140-3p at 16q22.
Finally, the integrative analysis based on
computational target prediction and miRNA/
mRNA profiling defined a network of puta-
tive functional miRNA-target regulatory rela-
tions supported by expression data. (Blood.
2009;114:e20-e26)
Introduction
Multiple myeloma (MM) is a malignant proliferation of bone
marrow (BM) plasma cells (PCs), characterized by a profound
genomic instability involving both numerical and structural chromo-
somal aberrations of potential prognostic relevance.1 Nearly half of
MM tumors are hyperdiploid (HD) with multiple trisomies of
nonrandom odd-numbered chromosomes and a low prevalence of
chromosomal translocations involving the immunoglobulin heavy
chain (IGH) locus at 14q32 and chromosome 13 deletion1; the
others are nonhyperdiploid (NHD) tumors often showing chromo-
some 13 deletion, 1q gain, and IGH translocations,2 with the most
frequent partners being 11q13, 4p16, 16q23, 20q11, and 6p21. The
deregulation of at least one of the cyclin D genes is observed in
almost all MM cases and, in combination with recurrent IGH
translocations, has been proposed for a molecular classification of
MM called translocation/cyclin (TC) classification.3,4 The occur-
rence of specific transcriptional patterns associated with the
molecular subgroups and major genetic lesions of MM has been
extensively described in several studies by us and others.2-10
miRNAs are endogenous approximately 22 nt RNAs that play
important regulatory roles in animals and plants by targeting
mRNAs for cleavage or translational repression.11 It has been
suggested that chromosomal abnormalities and other types of
genetic or epigenetic alterations might contribute to miRNA
deregulation in cancer.12,13
There are still few published data concerning miRNA expres-
sion in MM. Loffler et al have shown that interleukin-6 (IL-6)
regulates miR-21 transcription in IL-6–dependent human myeloma
cell lines (HMCLs) through a STAT-3–related mechanism, and that
ectopic miR-21 expression can sustain their growth in the absence
of IL-6.14 Pichiorri et al have reported a set of miRNAs that can be
associated with neoplastic transformation and progression in
MM.15 Our group has identified a set of deregulated miRNAs in
HMCLs that correlate with copy number (CN) alterations or gene
expression patterns.16,17 More recently, Roccaro et al reported the
down-regulation of miR-15a and miR-16 in a small cohort of
relapsed-refractory MM patients, showing that they may regulate
the proliferation and growth of MM cells in vitro and in vivo.18
We here describe the miRNA expression profiling of MMs in the
context of the major recurrent molecular alterations of the disease.
Furthermore, in an attempt to define the consequences of differential
miRNA expression, we searched for functional targeting relationships
by the definition of a global miRNA/mRNA regulatory network.
Methods
Patient samples
BM aspirates were obtained during standard diagnostic procedures from
54 untreated patients (48 MMs and 6 plasma cell leukemias [PCLs]), most
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of whom have been included in our previous reports.5,17 All patients had
given their informed consent in accordance with the Declaration of
Helsinki, and all studies were approved by the Institutional Review Board
of the Fondazione IRCCS Policlinico of Milan. Normal control samples
(NCs) were obtained from 3 healthy donors. Patients had been diagnosed on
the basis of previously described criteria.5 PCs were purified from BM
biopsies using CD138 immunomagnetic microbeads (MidiMACS; Miltenyi
Biotec).19 The purity of the positively selected PCs ( 90%) was assessed
by flow cytometry. Patients have been stratified according to the previously
described TC classification.3,4 Briefly, the TC1 group included patients
characterized by the t(11;14) or t(6;14) translocation; TC2, those showing
low to moderate levels of the CCND1 gene in the absence of any primary
IGH translocation; TC3, tumors that do not fall into any of the other groups;
TC4, cases that show t(4;14) translocation; and TC5, either the t(14;16) or
t(14;20) translocations.
miRNA expression profiling
Thirty-eight MM, 2 PCL, and 3 NC samples were investigated for miRNA
expression by microarray analysis. The patient samples were selected to be
representative of the 5 TC groups, and the PCL samples with translocated
MAF genes were included because of the relatively small number of TC5
MM patients. Fluorescence in situ hybridization information regarding the
major numerical chromosomal alterations was already available (supplemen-
tal Table 1, available on the Blood website; see the Supplemental Materials
link at the top of the online article). The total RNA extraction and quality
assessment were performed as previously described.16 The samples were
profiled on the Agilent Human miRNA Microarray V2 (Agilent Technolo-
gies), consisting of 60-mer DNA probes synthesized in situ that represent
723 human and 76 human viral miRNAs from the Sanger database (Version
10.1), using the one-color technique in accordance with the manufacturer’s
instructions.16 The human miRNAs data were reannotated on Sanger
Release 12.0 and normalized using the Aroma Light package for Bioconduc-
tor. To overcome scaling biases resulting from background subtraction, the
data were converted to obtain positive values throughout the dataset, at a
minimum value of 1. The raw and normalized microRNA data are available
through GEO accession number GSE17498. Hierarchical agglomerative
clustering of the selected probe lists was performed using Pearson
correlation coefficient and average linkage as distance and linkage metrics,
respectively.19 Supervised analyses were carried out using Significant
Analysis of Microarrays software, Version 3.02 as previously described.5
The significance threshold (at a q value  0) was determined tuning the 
parameter on the false discovery rate and controlling the q value of the
selected probes. The cross-validation of the identified signatures was
performed using the default options of lda package for Linear Discriminant
Analysis in R software, choosing Leave-One-Out Cross-Validation method and
applying a 1000-permutation model on a bootstrapped resampled dataset.
Quantitative RT-PCR
Selected mature miRNAs underwent quantitative reverse-transcribed poly-
merase chain reaction (RT-PCR) using TaqMan microRNA assays (Applied
Biosystems) as previously described.16
Gene expression profiling
The transcriptional profiles of the patients have been generated using
Affymetrix GeneChip HG-U133A arrays as previously described5,20 and are
available through GEO accession number GSE13591. The raw intensity
signals were extracted from CEL files and normalized using the RMA
“function of affy” package for Bioconductor and custom GeneAnnot-based
Chip Annotation Files, Version 2.0.1 (CDF)21 (available at http://
www.xlab.unimo.it/GA_CDF), thus leading to the definition of 12 195
unique well-characterized genes.
Genome-wide profiling
Nineteen of the 40 MM/PCL samples profiled for miRNA expression
underwent genome-wide DNA analysis using Affymetrix GeneChip Human
Mapping 50K XbaI microarrays, and the CN values were generated as
recently described.20 Briefly, raw CN values for individual SNPs and the
probability of loss of heterozygosity (LOH) were extracted from CEL files
and converted into signal intensities using Affymetrix GTYPE 4.1 and
CNAT 4.0.1 software; robust estimate of genotype calling was performed
using BRLMM distance classifier. Piecewise constant estimates of the
underlying local DNA CN variation were calculated using the DNAcopy
Bioconductor package, which looks for optimal breakpoints using circular
binary segmentation, and the estimated profiles were normalized using the
self-developed FBN package for R software. LOH was defined applying a
100-kb smoothing window (ie, 2-fold the mean intermarker distance on the
arrays) on the CNAT-derived value with a probability higher than 0.95 for
the detection of a monoallelic polymorphism.20 The CEL files are available
through GEO accession number GSE16121.
miRNA target prediction
miRNA targets have been predicted applying miRanda algorithm22 on
human miRNA and transcript sequences of miRBase Release 12.023 and
ENSEMBL Release 52, respectively. The score threshold of miRanda,
associated with each predicted miRNA-transcript targeting relationship and
depending on the sequence alignment and thermodynamic stability of the
RNA duplex, has been set at 160. Finally, the correspondence between
ENSEMBL_transcript and EntrezGene_ID was defined.
Integrative analysis of miRNA and gene expression profiles to
reconstruct a miRNA/gene regulatory network
The posttranscriptional regulatory network of miRNA and genes in MM has
been defined as a directed, bipartite graph in which miRNA-mRNA
relationships are supported by both targeting predictions and expression
data. Specifically, the network has been reconstructed using the subset of
miRNAs and genes characterized by (1) a regulatory relationship according
to miRanda predictions and (2) expression profiles strongly anticorrelated.
Indeed, because miRNAs tend to down-regulate target mRNAs, the
expression profiles of genuinely interacting pairs are expected to be
anticorrelated. Thus, for each miRNA/gene pair scored as potentially
interacting on the basis of miRanda prediction, the Pearson correlation
coefficient of the respective expression vectors in MM samples was
calculated and used as an estimator of the functional activity of the miRNAs
on the target genes. Genes were considered genuine miRNA targets when
included within the top 3% of all pairs ordered on their anticorrelation
score.24 This selection gave rise to the final adjacency matrix S of regulatory
relations supported by MM expression data and the associated miRNAs/
genes regulatory network. The matrix S defined a bipartite directed network
with 2 types of nodes (miRNAs and mRNAs) connected by directed edges,
each representing a probable functional regulatory effect of a miRNA on a
target gene. The posttranscriptional network allows identifying groups of
genes regulated by the same miRNA/s, and of miRNAs regulating specific
groups of genes of functional relevance. The networks were drawn using
Cytoscape,25 and the functional enrichment analysis was performed using
Database for Annotation, Visualization and Integrated Discovery 2008 Tool
(http://david.abcc.ncifcrf.gov/).
Statistical analysis
Conventional statistical procedures were applied using standard packages
for R software (Kendall  correlations, Wilcoxon rank-sum tests, t tests, and
Fisher exact tests).
Results
Global miRNA expression profiling in MM patients
MiRNA profiles were analyzed by high-density microarrays,
specific for 723 human miRNAs, in 40 patients representative of
the 5 TC groups (supplemental Table 1), and in PCs from 3 NCs. To
determine whether global miRNA profiling could distinguish the
molecular groups, we performed an unsupervised analysis using
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conventional hierarchical agglomerative clustering: the
43 samples were described by 74 miRNAs whose average change
in expression levels varied at least 2-fold from the mean across the
dataset.19 The most striking finding was that all of the TC4 patients
were tightly clustered (Figure 1, gray cluster, P  .001), as were
4 of 5 TC5 cases (red cluster, P  .001). The TC2 cases were
partially grouped (blue cluster, P  .005), whereas the TC1 and
TC3 samples were scattered along the dendrogram. The NCs were
clearly grouped in a distinct sub-branch.
Next, multiclass analysis allowed identifying a set of 26 miRNAs
showing highly significant differential expression (at q value 0)
across the 5 TC groups (supplemental Table 2). As shown in Figure 2A,
all of the TC groups except TC3 were characterized by the up-regulation
of specific miRNAs. In particular, 10 (38%) miRNAs (miR-150,
miR-133b, miR-99a, miR-133a, miR-155, miR-125b, let-7c, miR-1,
miR-155*, and miR-34b*) were expressed at higher levels in TC5 than
in the other classes, 7 (27%) in TC4 (miR-125a-5p, let-7e, miR-99b,
miR-222, miR-221, miR-221*, and miR-365), 6 (23%) in TC2 (miR-874,
miR-1237, miR-512-3p, miR-940, miR-933, and miR-1226*), and
3 (11%) in TC1 (miR-361-3p, miR-582-5p, and miR-30e*). Notably,
miR-125a-5p, let-7e, and miR-99b, which were associated with the
highest scores in the supervised analysis and overexpressed specifically
in the TC4 samples, belong to a cluster at 19q13.33, whereas mir-99a,
let-7c, and mir-125b-2, highly expressed in the TC5 cases, belong to a
paralogous cluster at 21q21.1. Figure 2B shows the 40 MM samples
clustered according to the expression profiles of the 26 miRNAs,
suggesting their capacity to drive TC distribution into separate branches.
To test the correctness of the obtained signature and its capability to
discriminate the 5 TC groups, we additionally tested the predictive
power of the 26 miRNAs using linear discriminant analysis for
classification of multivariate observations. The procedure led to confirm
the accuracy of the identified signature, at a percentage of an overall
classification rate of 89.3%: specifically, all TC1, TC4, and TC5 samples
were classified correctly, whereas TC2 and TC3 cases showed a
misclassification error of 32.8% and 11.1%, respectively.
We also investigated the differential miRNA expression on the
basis of the occurrence of other recurrent chromosomal alterations,
such as 1q gain and 13q and 17p deletions, and identified several
differentially expressed miRNAs, none of which was located in the
involved chromosomal region. Similarly, comparison of the HD
and NHD cases revealed a set of up-regulated miRNAs only in the
latter. Some of the miRNAs identified in these analyses were the
same as those found in IGH-translocated patients, in all likelihood
because of their representativeness within 1q gain, del(13), del(17),
and NHD cases (Figure 3).
Figure 1. Unsupervised analysis of miRNA expression profiles. Hierarchical
clustering of the samples using the 74 most variable miRNAs (patients in columns,
miRNAs in rows). The color scale bar represents the relative miRNA expression
changes normalized by the standard deviation. The patients’ molecular characteris-
tics are shown above the matrix; n indicates unavailable information. Specific
characteristics are enriched in colored sub-branches.
Figure 2. Identification of miRNA signatures characterizing TC classes.
(A) Heatmap of the differentially expressed miRNAs in MM patients stratified into the
5 TC groups. (B) Dendrogram of the 40 MM samples clustered according to the
expression profiles of the 26 miRNAs.
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Quantitative RT-PCR validation of differentially expressed
miRNAs
To validate the microarray data, the levels of some miRNAs
(miR-99b, miR-582-5p, miR-155, miR-30e*, miR-125b, miR-133b,
miR-221, miR-222, miR-125a-5p, and miR-99a) were quantified by
quantitative RT-PCR in all of the 43 samples. As shown in
supplemental Table 3, linear correlation analysis indicated a very
good correspondence between the 2 techniques.
Furthermore, the expression of miR-99b, miR-582-5p, miR-
133b, and miR-125a-5p was also evaluated in 14 additional cases,
4 cases of which carrying t(11;14), 7 t(4;14), and 3 t(14;16) or
t(14;20). Overall, in the 54-sample panel, miR-99b and miR-
125a-5p were confirmed as showing statistically significant and
specific overexpression in the t(4;14) group; miR-133b in the
t(14;16)/t(14;20) group; and miR-582-5p in the t(11;14) group
(P  .001 for all miRNAs; Figure 4).
Integrative analysis of miRNA expression profiles with
genome-wide copy number variations and occurrence of LOH
To evaluate the influence in miRNA expression of the allelic
imbalances detected at a genome-wide level, we performed an
integrative analysis of mature miRNA expression levels and their
inferred DNA CN values, available in 19 of 40 cases (supplemental
Table 1).20 The correlation analysis identified 49 mature miRNAs
(P  .05; supplemental Table 4), mainly localized on chromosome
1 (8 of 49, 16%), followed by chromosome 19 (6 of 49, 12%),
chromosome 17 (4 of 49, 8%), and chromosomes 3, 5, 11, 13, 14,
and 15 (3 of 49 each, 6%). Notably, miR-520a-5p, miR-518d-5p,
miR-498, and miR-520g belong to a cluster at 19q13.41, and
miR-17, miR-20a, and miR-20a* belong to the mir-1792 cluster
at 13q31.3.
Next, we tested the correlation between miRNA expression and
the occurrence of LOH, as defined in our previous report.20 We
identified the down-regulation of 14 miRNA genes in the presence
of LOH (supplemental Table 5): let-7b, mapped to 22q13.31
(P  .017), and miR-662 (16p13.3, P  .012) were the most
statistically significant. We also highlighted the intronic miRNA
miR-140-3p (P  .022), which maps to 16q22.1; the miR-19b and
miR-20a belonging to the mir-1792 cluster at 13q31.3 (P  .022
and .029, respectively); and miR-137 (P  .024), which maps
to 1p21.3.
Integrative analysis of miRNA/mRNA expression and
reconstruction of a regulatory network in MM
The integrative analysis of miRNA/mRNA expression profiles
allows reconstructing a network of functional interactions occur-
ring in MM from the panel of potential regulatory relationships
predicted from sequence information. Our integrative approach
assumes that the final effect of a truly functional interaction
between a miRNA and its predicted mRNA targets can be seen as a
pair of anticorrelated expression profiles. Thus, the set of MiRanda
predicted targeting relationships was refined selecting those more
strongly supported by the miRNA and mRNA expression data. The
entire procedure led to the identification of 23 729 regulatory
relationships, namely, anticorrelation, involving 628 miRNAs and
6435 predicted target genes, as approximately 47% of the genes
associated with an expression profile were not targets of any of the
considered miRNAs and 93 miRNAs (13%) were not significantly
anticorrelated with any target gene. The data from the integrative
analysis were used to reconstruct a bipartite direct miRNAs/
mRNAs regulatory network. The number of target genes per
miRNA ranged from 1 to 440 (average, 34; mean, 3.7 miRNAs per
gene; supplemental Table 6).
Various subnetworks can be derived from the global identified
network, as those accounting for the targeting relationships of
specific miRNA signatures associated with distinct TC groups.
Supplemental Figure 1 reports the subnetwork of the t(4;14)
miRNA signature, ie, one of the most consistent and specific
subgroups of our dataset. The network of t(4;14) consists of
7 miRNAs and 289 anticorrelated targets, with the number of
targets per miRNA ranging from 1 to 113, and approximately 29%
of the genes being targeted by at least 2 miRNAs. Interestingly,
Figure 3. Identification of miRNA signatures characterizing distinct MM genetic subgroups. Supervised analyses identifying the miRNAs that are differentially expressed
in MM patients harboring: (A) gain/amplification of the 1q arm, (B) del(13q14), (C) deletion of 17p, and (D) hyperdiploidy.
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3 genes are commonly regulated by 5 miRNAs (CBFA2T2,
core-binding factor, runt domain,  subunit 2, translocated to, 2;
PPP1R16B, protein phosphatase 1, regulatory inhibitor subunit
16B; and GOSR2, Golgi SNAP receptor complex member 2).
Functional enrichment analysis of anticorrelated targets revealed
various overrepresented biologic processes, including chromosome
segregation, protein polyubiquitination, cell cycle regulation, and
unfolded protein response (supplemental Table 7). Interestingly, a
comparison between the identified supported miRNA target genes
and mRNAs down-regulated in the t(4;14) cases (as identified in a
larger proprietary dataset of 132 MMs, data not shown) highlighted
that the miRNA targets were significantly enriched in down-
regulated genes (P  .001; supplemental Table 8). Similarly,
subnetworks were derived considering the sets of miRNAs differen-
tially expressed in TC5 and TC1 groups (supplemental Table 9).
Discussion
In this study, the integrative analysis of the different types of
genomic data (ie, miRNA and mRNA expression levels and
genome-wide CN profiles) allowed the definition of distinct
patterns of miRNA deregulation and the prediction of the miRNA/
mRNA regulatory networks in molecular subtypes of MM.
Particularly, our results highlighted that specific patterns of
miRNA expression may differentiate MMs with distinct and
well-known genetic alterations. Specific signatures were found to
be associated with t(4;14) or translocated MAF genes and, to a
lesser extent, with t(11;14) and TC2 group (expressing moderate
levels of CCND1 in the absence of IGH translocation). This
scenario is reminiscent of that previously described at mRNA level
in the context of the TC classification.4 Other chromosomal
abnormalities recurrently observed in MM samples (ie, 13q
deletion, 1q gain/amplification, 17p deletion, and the HD status)
appeared to be associated with less strong miRNA signatures, a
finding that needs to be clarified in larger series.
Most of the 26 miRNAs significantly discriminating the TC groups
have previously been found to be involved in solid and hematologic
tumors. The most extensively investigated are miR-155, miR-221 and
miR-222, and the let-7 family. MiR-155 is involved in many biologic
processes, including hematopoiesis, inflammation, and immunity, and
its deregulation has been found to be associated with certain types of
solid and hematologic tumors, in which it is predominantly overex-
pressed and acts as an oncomir.26 Notably, miR-155 has been very
recently found deregulated in Waldenstro¨m macroglobulinemia (WM),
suggesting a role in the proliferation and growth of WM cells acting on
signaling cascades, including MAPK/ERK, PI3/AKT, and nuclear
factor-B pathways.27 In addition, miR-155 knockdown leads to signifi-
cant increase of WM cells in G1 phase and to the down-regulation of
cyclin-dependent kinases and cyclins D and the simultaneous up-
regulation of p53 expression, suggesting a critical role in the regulation
of cell-cycle proteins responsible for G1 arrest.27 MiR-221 and miR-222
have also been found to be up-modulated in many tumors and described
to target the C-KIT, p27, and p57 genes.28,29 Finally, many human let-7
genes, which are known to target RAS genes and oncogenes involved in
the cell cycle, such as HMGA2, MYC, CDK6, and CDC25,30 map to
regions frequently deleted in human tumors, indicating that they may
function as tumor suppressors. The most striking finding was the very
specific expression of 3 miRNAs (miR-99b, let-7e, and miR-125a-5p),
encoded in a conserved genomic cluster, in the t(4;14) cases. They are
coordinately up-regulated during metamorphosis in Drosophila, where
they are cotranscribed as a single polycistronic transcript.31,32 Although
their involvement has been suggested in various tumors, to our
Figure 4. Quantitative RT-PCR validation of miRNA expres-
sion. Box plots of miRNAs quantified in quantitative RT-PCR in
the broadened panel of 54 MM-PCL cases, whose expression
significantly correlated with the presence of a specific IGH
translocation. Expression levels are given as 2Ct.
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knowledge, this is the first evidence of their coordinated deregulation
in cancer.
The differential miRNA expression associated with distinct
genetic subgroups is a novel finding in MM. Of note, it has already
been reported in other hematologic malignancies, such as acute
myeloid leukemia33 and chronic lymphocytic leukemia. As regards
this latter neoplasia, in which the role of miRNA has been
extensively investigated,34 the presence of miRNA signatures
associated with the major specific genetic lesions (trisomy 12 and
13q14, 11q23, and 17p13 deletions) has been reported very
recently.35 Interestingly, as found in our study, the discriminating
miRNAs were not localized in the chromosomal regions specific
for the corresponding cytogenetic abnormalities. Overall, the
identification of specific miRNA patterns may help not only to
distinguish distinct MM genetic subgroups known to show differ-
ences in term of response to therapy and survival, but also to
provide a better understanding of their pathogenesis.
We also evaluated the impact in miRNA expression of allelic
imbalances occurring in MM. Our integrative analysis identified the
occurrence of a gene dosage effect on the expression of several
miRNAs, as has previously been reported in HMCLs.16 Interestingly,
some of the miRNA genes map to hotspot-altered regions in MM: for
example, mir-17 and mir-20a, which belong to a cluster at 13q31, which
was deleted in almost 40% of our patients; furthermore, a number are
located in odd-numbered chromosomes involved in hyperdiploidy,
particularly chromosomes 3, 5, 7, 9, 11, and 19; and 3 (mir-1231,
mir-205, and mir-215) belong to the long arm of chromosome 1, which
was gained at a frequency of more than 30%. Using the analog
integrative approach, we evaluated the impact of LOH on miRNA
expression, based on the data described in our recently published
study.20 Among the identified miRNA whose expression correlated with
the occurrence of LOH, let-7b has been previously reported as the most
discriminatory miRNA between acute lymphoid leukemia cases com-
pared with acute myeloid leukemia cases (significantly down-regulated
in acute lymphoid leukemia).36 Moreover, it has been demonstrated that
let-7b correlated with the cytogenetic prognostic risk associated with the
samples, being low in the favorable groups and high in intermediate and
adverse acute myeloid leukemia cases.37 Of note, we also identified a
significant correlation between miR-140-3p expression and the occur-
rence of LOH at 16q22.1-q23.1, which has been described as recurrent
in MM by others and us.20,38 We have also demonstrated that LOH at
16q22.1 significantly correlated with the expression of WWP2,20 host
gene of miR-140-3p involved in ubiquitination processes, suggesting
that LOH (associated with monoallelic loss or other mechanisms, such
as uniparental disomy) may also represent an important mechanism in
the coordinated control of miRNA and gene expression in MM.
The computational prediction of miRNA targets currently presents
several significant challenges because all of the most widely used tools
(miRanda, TargetScan, PicTar, PITA, and RNAhybrid) are characterized
by a significant proportion of false-positive interactions39,40 that are
partly because posttranscriptional regulation is context-dependent. On
the basis of increasing experimental evidence supporting the hypothesis
that miRNAs can act through target degradation, it has been proposed
that target predictions could be integrated with miRNA and gene
expression profiles to select functional miRNA/mRNA relationships.
This can be done by adopting a variational Bayesian model and
software,41,42 or simply using a nonheuristic method based on
miRNA/mRNA anticorrelations. We applied the latter to our
dataset, which allowed the reconstruction of a general miRNA/
mRNA regulatory network that represents the putative functional
regulatory effects (as supported by expression data) of all of these
miRNAs on their targets in MM.
On the basis of the target genes identified here, several the miRNAs
differentially expressed in IGH translocated cases may play important
roles in the biology of MM PCs. With regard to the t(4;14) miRNA
signature, 5 miRNAs target CBFA2T2, a nuclear repressor homologous
to ETO that binds to the AML1-ETO complex and may play a role in
hematopoietic differentiation.43,44 Furthermore, let-7e targets PTPRE, a
positive regulator of osteoclast function45 and a selective inhibitor of
IL-6– and IL-10–induced JAK-STAT signaling.46 Interestingly, the
expression of the tumor suppressor gene PDCD4 (programmed cell
death 4),47 a supported target of miR-221 based on our analysis, has
recently been found to depend on the levels of MMSET, which is
deregulated by the t(4;14).48 ING4, a tumor suppressor frequently
mutated or down-regulated in human cancers, which was recently
described to exert an inhibitory effect on MM-induced angiogenesis,49,50
is a supported target of miR-365. Concerning the TC5 signature,
miR-133a targets DMTF1, a putative tumor suppressor that activates the
ARF-p53 pathway, leading to cell growth arrest or apoptosis; notably, it
maps at 7q21, often deleted in human malignancies.51 Finally, among
the miRNAs up-regulated in t(11;14), miR-361-3p and miR-30e* target
PPP2R4, an activator subunit of PP2A, which plays an important role in
the survival and growth of MM cells because it dephosphorylates the
GP130 subunit of the IL-6 receptor, thus preventing its degradation and
allowing the activation of IL-6 signaling.52,53
Taken together, our findings strongly suggest that understanding
the molecular biology of myeloma requires considering the
miRNome in the context of the genomic and transcriptomic
features of malignant PCs. Based on this integrated approach, our
data may provide an important contribution to future investigations
aimed at characterizing the role of specific miRNAs in MM
pathogenesis.
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